VP, Business Development, Cardiovascular, Metabolism & Retina
Michael Genus is Vice President, Business Development, Cardiovascular, Metabolism & Retina for Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads the development and execution of all business development plans in support of the Cardiovascular, Metabolism & Retina Therapeutic Area. He oversees transactions and acquisitions, as well as scientific licensing and alliance management with strategic partners, with responsibility for bringing new compounds and businesses to Janssen. He also has responsibility for Janssen divestitures.
Prior to his current position, Mike was Senior Director, Mergers & Acquisitions and Business Development. In this role, he led the development and execution of strategies related to corporate development and M&A for the Janssen Immunology Therapeutic Area, including the $6.5B Momenta acquisition in 2020, and was responsible for identifying, evaluating and championing new business opportunities as part of the Immunology Commercial Franchise.
Since joining Johnson & Johnson, Mike has held a variety of leadership positions in Marketing, Sales, Business Analytics and Operations across Global Strategic Marketing, Tibotec Therapeutics, Internal Medicine and Immunology organizations. Before joining Johnson & Johnson, Mike spent seven years at Bristol-Myers Squibb Company where he held a series of positions including Managed Health Care Operations, U.S. Pricing and Economics, Business Development Analysis and Director, Strategic Analysis.
Mike holds a B.S. with a dual major in Finance and Management Information Systems from Syracuse University.